Asston Pharmaceuticals Share Price
107.80+2.15 (+2.04%)
+6.87% past 1 Year
Asston Pharmaceuticals is engaged in the manufacturing and export of both pharmaceutical formulations and nutraceutical products in domestic and various African markets. The company operates under brand ‘Asston’. The company
Corporate filings & documents
Announcements
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Prakruti R Pali
4 hours agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Prakruti R Pali
2 days agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Prakruti R Pali
2 days agoThe Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Prakruti R Pali
3 days agoThe Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Prakruti R Pali
3 days agoThe Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Prakruti R Pali
3 days agoThe Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Prakruti R Pali
3 days agoAsston Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/09/2026 inter alia to consider and approve 1. Appointment of M/s Panchal S K & Associates (Peer Review Certificate No.: 018089 and Firm Registration No.: 145989W) as Statutory Auditor of the Company;2. The directors retiring by rotation;3. The date and draft notice of the 7th Annual General Meeting of the Company;4. Other incidental matters
1 week agoAsston Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/09/2026 inter alia to consider and approve 1. Appointment of M/s Panchal S K & Associates (Peer Review Certificate No.: 018089 and Firm Registration No.: 145989W) as Statutory Auditor of the Company;2. The directors retiring by rotation;3. The date and draft notice of the 7th Annual General Meeting of the Company;4. Other incidental matters
1 week agoVoting Result and Scrutinizer report for EGM held on 31st July 2026 through VC-OAVM
1 month agoVoting Result and Scrutinizer report for EGM held on 31st July 2026 through VC-OAVM
1 month agoOutcome and Proceedings of the 2nd Extraordinary General Meeting for F.Y. 2026-27 scheduled to be held on 31st July 2026 at 12:30 P.M. through Video Conferencing and Other Audio-Visual Means.
1 month agoOutcome and Proceedings of the 2nd Extraordinary General Meeting for F.Y. 2026-27 scheduled to be held on 31st July 2026 at 12:30 P.M. through Video Conferencing and Other Audio-Visual Means.
1 month agoCertificate under regulation 74(5) of SEBI (Depositories Participants) Regulation 2018.
1 month agoCertificate under regulation 74(5) of SEBI (Depositories Participants) Regulation 2018.
1 month agoNewspaper Publication
1 month agoNewspaper Publication
1 month agoNotice of Second Extraordinary General Meeting for F.Y. 2026-27
1 month agoNotice of Second Extraordinary General Meeting for F.Y. 2026-27
1 month agoMeeting Update
2 months agoMeeting Update
2 months agoAnnouncement regarding Extraordinary General Meeting of the Company.
2 months agoAnnouncement regarding Extraordinary General Meeting of the Company.
2 months agoUpdate on Board Meeting Scheduled to be held on 02nd July 2026.
2 months agoUpdate on Board Meeting Scheduled to be held on 02nd July 2026.
2 months agoDisclosure under regulation 30 (LODR)- Preferential Issue
2 months agoDisclosure under regulation 30 (LODR)- Preferential Issue
2 months agoOutcome of the Board Meeting Scheduled to be held on 02nd July 2026.
2 months agoOutcome of the Board Meeting Scheduled to be held on 02nd July 2026.
2 months agoTrading Window Closure
2 months agoTrading Window Closure
2 months agoAsston Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/07/2026 inter alia to consider and approve proposal for raising of funds through any or all of various methods including by way of preferential issue
2 months agoAsston Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/07/2026 inter alia to consider and approve proposal for raising of funds through any or all of various methods including by way of preferential issue
2 months agoAudited Financial Results for the Financial Year ended 31st March 2026
3 months agoAudited Financial Results for the Financial Year ended 31st March 2026
3 months agoOutcome of Board Meeting scheduled to be held on 29th May 2026
3 months agoOutcome of Board Meeting scheduled to be held on 29th May 2026
3 months agoAsston Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 inter alia to consider and approve 1. To consider and approve the Audited Financial Statements and Financial Results along with the Audit report for the Financial Year and Quarter ended 31st March 2026;2. To consider and approve the statement of deviation of funds pursuant to Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015;3. Other Incidental Matter.
3 months agoAsston Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 inter alia to consider and approve 1. To consider and approve the Audited Financial Statements and Financial Results along with the Audit report for the Financial Year and Quarter ended 31st March 2026;2. To consider and approve the statement of deviation of funds pursuant to Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015;3. Other Incidental Matter.
3 months ago<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Asston Pharmaceuticals Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>U24304MH2019PLC324187</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>5.04</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>NA</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: RISHI UPADHAYA <br/> Designation: COMPANY SECRETARY <br/> EmailId: [email protected]</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: SUMIT PAWAR <br/> Designation: CFO <br/> EmailId: [email protected]</div> </div> <div> <br/> Date: 30/04/2026<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>
4 months agoVoting Result and Scrutinizers Report for EGM held on 28th April 2026 through VC-OAVM
4 months agoVoting Result and Scrutinizers Report for EGM held on 28th April 2026 through VC-OAVM
4 months agoOutcome and Proceedings of the Extraordinary General Meeting held on 28th April 2026 through (VC-OAVM).
4 months agoOutcome and Proceedings of the Extraordinary General Meeting held on 28th April 2026 through (VC-OAVM).
4 months agoNon-Applicability of Reg 24(A) of SEBI (LODR) Regulation 2015 Annual Secretarial Compliance Report.
4 months agoNon-Applicability of Reg 24(A) of SEBI (LODR) Regulation 2015 Annual Secretarial Compliance Report.
4 months agoCertificate under regulation 74(5) of SEBI (Depositories Participants) Regulation 2018
4 months agoCertificate under regulation 74(5) of SEBI (Depositories Participants) Regulation 2018
4 months agoIntimation of record date i.e. 17th April 2026 for the E-voting process pursuant to the Extraordinary General Meeting scheduled to be held on 28th April 2026
5 months agoIntimation of record date i.e. 17th April 2026 for the E-voting process pursuant to the Extraordinary General Meeting scheduled to be held on 28th April 2026
5 months agoAnnual reports
Concalls & investor presentations
No presentations found
Corporate Actions
Date
Type
Details
No data available.
Company details
Registered office
4th Floor, Office No A-431 Balaji Bhavan, Plot No 42 A Sector-11 Cbd Belapur, Navi Mumbai Thane Maharashtra PIN: 400614 Tel No: 022 49731419 / 49731411 Fax No: NULL Email: [email protected] Internet: www.asstonpharmaceuticals.com
Registrars
451, Krishna Apra BusinessSquare, Netaji Subhash Place,Pitampura, New Delhi – 110034 451, Krishna Apra Business Square, Netaji Subhash Place, Pitampura PIN: Tel No: NULL Fax No: NULL Email: NULL
Management
Ashish Narayan Sakalkar, Managing Director
Saili Jayaram More, Whole Time Director & Chief Executive Officer
Sachin Chandrakant Badakh, Non Executive Director
Rishabh Kumar Jain, Non Executive Independent Director
Vijaya Shahpurkar, Non Executive Independent Director
Rishi Upadhaya, Company Secretary and Compliance officer
Yogesh Supekar, Non Executive Independent Director
Details
BSE 544445
NSE NULL
ISIN INE0SJX01015